Pricing Log in Create free account

CASI Pharmaceuticals Inc. (CASIF) vs IN8bio, Inc. (INAB)

CASI Pharmaceuticals Inc. and IN8bio, Inc. are both Biotechnology companies. CASI Pharmaceuticals Inc. and IN8bio, Inc. are of similar size ($12.4M and $11.7M). IN8bio, Inc. has the higher net margin (0.00% vs −232.0%) and the lower return on invested capital (−2,948.6% vs 0.00%). Across the 13 metrics below, IN8bio, Inc. leads on 7 and CASI Pharmaceuticals Inc. on 6.

Valuation

Metric CASIF INAB Biotechnology median
P/E n/m n/m 8.50
P/S 0.09 n/m 9.71
P/B n/m 1.18 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1.79 n/m 9.21
Earnings yield (2,580.00%) (145.95%) (33.15%)
Free cash flow yield (3,801.00%) (67.71%) (25.50%)

Profitability

Metric CASIF INAB Biotechnology median
Gross margin 48.65% 0.00% 65.16%
Operating margin (206.87%) 0.00% 0.00%
Net margin (232.03%) 0.00% 0.00%
Free cash flow margin (340.20%) 0.00% 0.00%
Return on equity 0.00% (111.11%) (56.36%)
Return on assets 0.00% (90.80%) (48.04%)
Return on invested capital 0.00% (2,948.56%) 0.00%

Growth

Metric CASIF INAB Biotechnology median
Revenue growth (TTM) (27.42%) — 6.02%
EPS growth (last fiscal year) (1.17%) 74.06% 30.26%
Revenue growth, 5-year CAGR 6.47% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CASIF INAB Biotechnology median
Debt to equity (0.34) 0.00 0.00
Current ratio 0.15 8.21 4.72
Net debt to EBITDA (0.43) 1.56 0.96

Dividend

Metric CASIF INAB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CASIF INAB Biotechnology median
Market cap 12.39m 11.68m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack